Invatec Supraortic Line ישראל - עברית - Ministry of Health

invatec supraortic line

אינטרומדיקס בע"מ - רופא - רדיולוגיה פולשנית / אנגיו

Invatec Peripheral Line ישראל - עברית - Ministry of Health

invatec peripheral line

אינטרומדיקס בע"מ - רופא - רדיולוגיה פולשנית / אנגיו

Invatec Coronary Line ישראל - עברית - Ministry of Health

invatec coronary line

אינטרומדיקס בע"מ - רופא - רדיולוגיה פולשנית / אנגיו

mamlite-automatic mammography system ישראל - עברית - Ministry of Health

mamlite-automatic mammography system

cintec medical ltd - רופא - מערכת ממוגרפיה אוטומטית ממוחשבת

Fingertip Pulse Oximeter ישראל - עברית - Ministry of Health

fingertip pulse oximeter

אסיא טכנולוגיות בע"מ - כלל האוכלוסיה - מכשיר לבדיקת רמת החמצן בדם ודופק החולה

פרימולוט-נור ישראל - עברית - Ministry of Health

פרימולוט-נור

bayer israel ltd - norethisterone acetate - טבליה - norethisterone acetate 5 mg - norethisterone - norethisterone - oral progestron for: dysfunctional bleeding, primary and secondary amenorrhea, premenstrual syndrome, timing of mensturation and endometriosis.

ארימידקס ישראל - עברית - Ministry of Health

ארימידקס

taro international ltd, israel - anastrozole - טבליות מצופות פילם - anastrozole 1.0 mg - anastrozole - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

היירימוז ישראל - עברית - Ministry of Health

היירימוז

novartis israel ltd - adalimumab - תמיסה להזרקה - adalimumab 50 mg/ml - adalimumab

בינוקריט 1000 יחבל 0.5 מל ישראל - עברית - Ministry of Health

בינוקריט 1000 יחבל 0.5 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 2000 יחבל 1 מל ישראל - עברית - Ministry of Health

בינוקריט 2000 יחבל 1 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 2000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob